Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 26;102(6):e208051.
doi: 10.1212/WNL.0000000000208051. Epub 2024 Feb 23.

Clinical Characteristics and Long-Term Outcomes of Late-Onset Multiple Sclerosis: A Swedish Nationwide Study

Elena F Mouresan  1 , Eleni Mentesidou  1 , Anders Berglund  1 , Kyla A McKay  1 , Jan Hillert  1 , Ellen Iacobaeus  1
Affiliations

Clinical Characteristics and Long-Term Outcomes of Late-Onset Multiple Sclerosis: A Swedish Nationwide Study

Elena F Mouresan et al. Neurology. .

Erratum in

Abstract

Background and objectives: Clinical onset of multiple sclerosis (MS) after the age of 50 years is uncommon and associated with a less favorable natural history. The differences in long-term outcomes in patients with late-onset MS (LOMS, onset 50 years or older) and adult-onset MS (AOMS, onset 18 years or older and younger than 50 years) during the disease-modifying therapy (DMT) era have been less studied. This study aimed to compare patient characteristics, DMT exposure, and disability progression in Swedish patients with LOMS and AOMS over 2 decades (2001-2022).

Methods: The nationwide Swedish MS registry was searched for patients with an onset of MS between January 1, 2001, and December 31, 2018, with symptom onset at age 18 years or older and ≥2 recorded Expanded Disability Status Scale (EDSS) scores. Clinical and demographic parameters and exposure to DMT were compared between LOMS and AOMS. Time to disability milestones (EDSS 4 and 6) was assessed using Kaplan-Meier curves and Cox proportional hazards regression models adjusted for sex, disease course, calendar year at onset, and DMT exposure.

Results: Among 8739 patients with MS who met inclusion criteria, 1,028 (11.8%) were LOMS. Primary progressive MS was more frequently diagnosed in LOMS compared with that in AOMS (25.2% vs 4.5%; p < 0.001). Most of the patients had been prescribed DMT, but more rarely in LOMS compared with AOMS (74.7% vs 95.6%; p < 0.001). Less than half of patients with LOMS had been exposed to a high-efficacy DMT (45.8%) compared with 73.5% of AOMS (p < 0.001). The risk of reaching disability milestones was greater for LOMS compared with that for AOMS (EDSS 4; adjusted hazard ratio [aHR] 2.71; 95% CI 2.22-3.30; p < 0.001, and EDSS 6; aHR 2.67; 95% CI 2.12-3.36; p < 0.001).

Discussion: This study distinguishes LOMS as a particularly vulnerable group and clinically supports close vigilance of these patients. Further studies are needed to assess and clarify the benefit of DMT usage in older adults with MS.

PubMed Disclaimer

Conflict of interest statement

E.F. Mouresan, E. Mentesidou, and A. Berglund declare no conflict of interest: K.A. McKay has received speaker honoraria from Biogen and Sanofi-Aventis and is funded by the Swedish Research Council for Health, Working Life and Welfare, and StratNeuro. J. Hillert received honoraria for serving on advisory boards for Biogen, Bristol-Myers-Squibb, Janssen, Merck KGaA, Novartis, Sandoz, and Sanofi-Genzyme and speaker's fees from Biogen, Janssen, Novartis, Merck, Teva, Sandoz, and Sanofi-Genzyme. He has served as PI for projects sponsored by, or received unrestricted research support from, Biogen, Bristol-Myers-Squibb, Janssen, Merck KGaA, Novartis, Roche, and Sanofi-Genzyme. His MS research is funded by the Swedish Research Council and the Swedish Brain foundation. E. Iacobaeus has received honoraria for serving on advisory boards for Biogen, Sanofi-Genzyme, and Merck and speaker's fees from Biogen and Sanofi-Genzyme. She has received funding from Region Stockholm Clinical Research Appointment and the Lindholm Fredholms foundation. Go to Neurology.org/N for full disclosures.

Figures

Figure 1
Figure 1. Flowchart of Patient Inclusion
EDSS = Expanded Disability Status Scale; MS = multiple sclerosis.
Figure 2
Figure 2. Treatment Exposure in the Study Population
(A) Late-onset multiple sclerosis (LOMS); (B) Adult-onset multiple sclerosis. PPMS = primary progressive multiple sclerosis; RRMS = relapsing-remitting multiple sclerosis. Modest (efficacy) DMT: interferon beta-1a, interferon beta-1b, pegylated interferon beta-1a, glatiramer acetate, dimethyl fumarate, and teriflunomide. High (efficacy) DMT: rituximab, ocrelizumab, natalizumab, alemtuzumab, fingolimod, cladribine, daclizumab, and autologous hematopoietic stem cell transplantation.
Figure 3
Figure 3. Kaplan-Meier Curves of Time to Confirmed Sustained EDSS 4 and 6
Total cohort (A), RRMS subcohort (B), PPMS subcohort (C). AOMS = adult-onset multiple sclerosis; LOMS = late-onset multiple sclerosis; PPMS = primary progressive multiple sclerosis; RRMS = relapsing-remitting multiple sclerosis.
See this image and copyright information in PMC

References

    1. Naseri A, Nasiri E, Sahraian MA, Daneshvar S, Talebi M. Clinical features of late-onset multiple sclerosis: a systematic review and meta-analysis. Mult Scler Relat Disord. 2021;50:102816. doi: 10.1016/j.msard.2021.102816 - DOI - PubMed
    1. Weinshenker BG, Rice GP, Noseworthy JH, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. Brain. 1991;114(Pt 2):1045-1056. doi: 10.1093/brain/114.2.1045 - DOI - PubMed
    1. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain. 1993;116(Pt 1):117-134. doi: 10.1093/brain/116.1.117 - DOI - PubMed
    1. Confavreux C, Vukusic S. Age at disability milestones in multiple sclerosis. Brain. 2006;129(Pt 3):595-605. doi: 10.1093/brain/awh714 - DOI - PubMed
    1. Scalfari A, Neuhaus A, Daumer M, Ebers GC, Muraro PA. Age and disability accumulation in multiple sclerosis. Neurology. 2011;77(13):1246-1252. doi: 10.1212/WNL.0b013e318230a17d - DOI - PMC - PubMed